Rhythm's Imcivree Scores FDA Approval in Bardet-Biedl Syndrome

The U.S. Food and Drug Administration has approved Boston-based Rhythm Pharmaceutical’s Imcivree (setmelanotide) for patients with Bardet-Biedl syndrome (BBS), a rare genetic disease with a wide range of symptoms, including severe obesity.